Daiichi Sankyo : FY2021 Financial Results Presentation

DAIICHI SANKYO CO., LTD.

Sunao Manabe

President and CEO

April 27, 2022

Forward-Looking Statements

Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo's future prospects. These forward-looking statements were determined by Daiichi Sankyo based on information obtained as of today with certain assumptions, premises and future forecasts, and thus, there are various inherent risks as well as uncertainties involved. As such, please note that actual results of Daiichi Sankyo may diverge materially from Daiichi Sankyo's outlook or the content of this material. Furthermore, there is no assurance that any forward-looking statements in this material will be realized. Regardless of the actual results or facts, Daiichi Sankyo is not obliged and does not have in its policy the duty to update the content of this material from the date of this material onward.

Some of the compounds under discussion are investigational agents and are not approved by the FDA or any other regulatory agency worldwide as a treatment for indications under investigation. Efficacy and safety have not been established in areas under investigation. There are no guarantee that these compounds will become commercially available in indications under investigation.

Daiichi Sankyo takes reasonable care to ensure the accuracy of the content of this material, but shall not be obliged to guarantee the absolute accuracy, appropriateness, completeness and feasibility, etc. of the information described in this material. Furthermore, any information regarding companies, organizations or any other matters outside the Daiichi Sankyo Group that is described within this material has been compiled or cited using publicly available information or other information, and Daiichi Sankyo has not performed in-house inspection of the accuracy, appropriateness, completeness and feasibility, etc. of such information, and does not guarantee the accuracy thereof.

The information described in this material may be changed hereafter without notice. Accordingly, this material or the information described herein should be used at your own judgment, together with any other information you may otherwise obtain.

This material does not constitute a solicitation of application to acquire or an offer to sell any security in the United States, Japan or elsewhere.

This material disclosed here is for reference purposes only. Final investment decisions should be made at your own discretion.

Daiichi Sankyo assumes no responsibility for any damages resulting from the use of this material or its content, including without limitation damages related to the use of erroneous information.

Agenda

• 1 FY2021 Financial Results

• 2 FY2022 Forecast

• 3 Business Update

• 4 R&D Update

• 5 5-Year Business Plan Update

• 6 Appendix

Overview of FY2021 Results

(Bn JPY)

FY2020 Results	FY2021 Results	YoY
Revenue	962.5	1,044.9	+8.6%	82.4
Cost of sales *	337.8	348.0	10.3
SG&A expenses *	318.5	352.1	33.7
R&D expenses *	227.4	254.1	26.7
Core operating profit*	78.9	90.6	+14.9%	11.8
Temporary income *	0.6	3.9	3.4
Temporary expenses*	15.6	21.5	5.9
Operating profit	63.8	73.0	+14.5%	9.2
Profit before tax	74.1	73.5	-0.6
Profit attributable to owners	76.0	67.0	-11.8%	-9.0
of the Company
Currency RateUSD/JPY EUR/JPY	106.06	112.38	+6.32
123.70	130.56	+6.86

* As an indicator of ordinary profitability, "core operating profit" which excludes temporary income and expenses from operating income is disclosed.

Income and expenses related to: sale of fixed assets, restructuring (excluding the sales of pipeline and launched products), impairment, loss compensation, reconciliation, and other non-temporary and material gains and losses are included in the "temporary income and expenses".

Temporary income and expenses are excluded from results and forecast for cost of sales, SG&A expenses and R&D expenses shown in the list above.

The adjustment table from operating profit to core operating profit is stated in the reference data

Increased by 82.4 Bn JPY (Increased by 53.7 Bn JPY excl. forex impact)

(incl. Innovative Pharmaceuticals,

(Asia, South and Central America)

EU Specialty Business9.9

Regulatory Milestone etc.

Oncology Business*118.3

Generic, Vaccines, OTC)

Enhertu, Dato-DXd*2

American Regent19.3

Upfront Payment &

FY2021 ResultsFY2020 Results

Japan Business

Forex Impact*328.7

Oncology Business

DS-8201/DS-1062

American Regent

Japan Business

ASCA Business

FY2020 Results

Business

EU Speciality

Forex Impact

FY2021 Results

800.0P8o5s0.i0tive F9a0c0t.0ors

950.0Nega1t,0i0v0e.0Fact1o,0r5s0.0

*1 Revenue for Daiichi Sankyo, Inc. and Daiichi Sankyo Europe's oncology products *2 Dato-DXd: Datopotamab deruxtecan (DS-1062)

*3 Forex impact USD: +12.7, EUR : +7.2, ASCA: +8.7

Positive Factors

(Bn JPY)

Negative Factors

Japan Business Unit

Lixiana+15.1

Tarlige

+9.6

Emgality

+4.6

Daiichi Sankyo Espha+11.4

Ezetimibe AG and others

Injectafer +5.9

GE injectables+9.8

EU Specialty Business Unit

Lixiana+15.1

Oncology Business*1 Unit

Nexium	-39.6
Memary	-11.0
Enhertu+5.2
Olmesartan	-3.8
Gain on sales of transferring	-3.1
current products
Olmesartan	-2.3

Enhertu+25.6

American Regent Unit

Enhertu, Dato-DXd*2 Upfront Payment & Regulatory Milestone etc.

Enhertu quid related payment+3.4

Dato-DXd upfront payment+2.1